Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVRNASDAQ:EQNASDAQ:MEIPOTCMKTS:SRNEQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.90-2.0%$5.77$7.96▼$24.15$14.63M0.6316,448 shs16,200 shsEQEquillium$0.36+2.8%$0.43$0.34▼$1.51$12.86M2.06358,948 shs84,313 shsMEIPMEI Pharma$2.23+1.8%$2.07$1.46▼$4.10$14.85M0.2144,334 shs1,719 shsSRNEQSorrento Therapeutics$0.00-23.5%$0.00$0.00▼$0.42$717K2.25511,766 shs17,913 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-2.03%+3.94%-53.75%-70.41%-82.96%EQEquillium0.00%-11.35%-12.22%-52.89%-73.92%MEIPMEI Pharma0.00%+3.48%+8.78%-12.89%-23.63%SRNEQSorrento Therapeutics-23.53%0.00%+44.44%+160.00%-87.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AEQEquillium2.9538 of 5 stars3.25.00.00.02.91.70.6MEIPMEI Pharma2.0667 of 5 stars0.03.00.04.13.30.81.3SRNEQSorrento TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AEQEquillium 2.33Hold$3.00733.56% UpsideMEIPMEI Pharma 2.00HoldN/AN/ASRNEQSorrento Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SRNEQ, EQ, MEIP, and ALVR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025EQEquilliumLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/28/2025EQEquilliumLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$3.00 ➝ $1.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AEQEquillium$30.41M0.42N/AN/A$0.64 per share0.56MEIPMEI Pharma$65.30M0.23$5.07 per share0.44$3.32 per share0.67SRNEQSorrento Therapeutics$62.84M0.01N/AN/A($0.05) per share-0.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)EQEquillium-$13.34M-$0.39N/AN/AN/A-10.05%-20.68%-10.77%8/6/2025 (Estimated)MEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-84.92%-67.53%N/ASRNEQSorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/AN/ALatest SRNEQ, EQ, MEIP, and ALVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q3 2025MEIPMEI PharmaN/A-$0.39N/A-$0.39N/AN/A3/27/2025Q4 2024EQEquillium-$0.22-$0.16+$0.06-$0.16N/A$4.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ASRNEQSorrento TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78EQEquilliumN/A3.043.04MEIPMEI PharmaN/A10.6610.66SRNEQSorrento TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%EQEquillium27.05%MEIPMEI Pharma52.38%SRNEQSorrento Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%EQEquillium31.60%MEIPMEI Pharma3.12%SRNEQSorrento Therapeutics2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableEQEquillium4035.72 million24.70 millionNot OptionableMEIPMEI Pharma1006.66 million6.46 millionOptionableSRNEQSorrento Therapeutics800551.28 million536.95 millionNot OptionableSRNEQ, EQ, MEIP, and ALVR HeadlinesRecent News About These CompaniesSorrento Therapeutics Restructuring Chief Hosted Party for Judges Who Later Oversaw Its LiquidationSeptember 3, 2024 | wsj.comSorrento, Naples, Italy Weather Conditionsstar_ratehomeAugust 29, 2024 | wunderground.comSorrento, British Columbia, Canada 10-Day Weather Forecaststar_ratehomeAugust 26, 2024 | wunderground.comSorrento Announces New Board MemberAugust 22, 2024 | br.advfn.comSorrento wins DoJ’s venue-based challenge to bankruptcy filingMarch 12, 2024 | msn.comSorrento’s Bankruptcy Venue Action Is ‘Unprecedented,’ DOJ SaysMarch 9, 2024 | news.bloomberglaw.comLatham, Jackson Walker avoid sanctions over bankruptcy forum shopping disputeFebruary 29, 2024 | reuters.comVirpax reaches deal to settle litigation with Sorrento Therapeutics, Scilex PharmaceuticalsFebruary 27, 2024 | bizjournals.comSorrento Therapeutics Stock (OTC:SRNEQ) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comSorrento faked venue in bankruptcy filing, Justice Department saysFebruary 21, 2024 | msn.comSorrento Therapeutics Inc (SRNEQ) Earnings Dates & ReportsNovember 18, 2023 | investing.comScilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate ...October 7, 2023 | bakersfield.comScilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock PriceOctober 7, 2023 | finance.yahoo.comScilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted ...October 4, 2023 | bakersfield.comScilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding CompanyOctober 3, 2023 | finance.yahoo.comScilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.September 21, 2023 | finance.yahoo.comScilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)September 14, 2023 | finance.yahoo.comScilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful BidderSeptember 13, 2023 | finance.yahoo.comSorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19September 12, 2023 | finance.yahoo.comScilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available InformationSeptember 11, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWill Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?By Gabriel Osorio-Mazilli | May 22, 2025View Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?Top 4 ETFs for China Exposure After Tariff Relief By Nathan Reiff | May 17, 2025View Top 4 ETFs for China Exposure After Tariff Relief 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%Buffett's Top 5 Stock Holdings Ahead of Next 13F FilingBy Ryan Hasson | May 2, 2025View Buffett's Top 5 Stock Holdings Ahead of Next 13F FilingStrategists Say Hold: Stocks May Beat the 'Sell in May' TrendBy Jeffrey Neal Johnson | May 9, 2025View Strategists Say Hold: Stocks May Beat the 'Sell in May' TrendSRNEQ, EQ, MEIP, and ALVR Company DescriptionsAlloVir NASDAQ:ALVR$2.90 -0.06 (-2.03%) As of 05/30/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Equillium NASDAQ:EQ$0.36 +0.01 (+2.83%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.38 +0.03 (+6.97%) As of 05/30/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.MEI Pharma NASDAQ:MEIP$2.23 +0.04 (+1.83%) Closing price 05/30/2025 03:50 PM EasternExtended Trading$2.18 -0.05 (-2.24%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Sorrento Therapeutics OTCMKTS:SRNEQ$0.0013 0.00 (-23.53%) As of 05/30/2025Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
